Xanthorrhizol: Anti-Inflammatory and Anticancer Research, Led By the One Negative Human Trial

Xanthorrhizol is the compound that makes temulawak chemically distinct from ordinary turmeric, and the main page correctly identifies anti-inflammatory and anticancer activity as its two best-studied preclinical properties. What the main page does not have room to cover is the depth of that cell-and-animal literature, or the single most important fact this research turned up: a real, registered, double-blind, placebo-controlled human trial of whole Curcuma xanthorrhiza — not just the isolated marker compound — exists, was conducted in an actual inflammatory disease, and found no benefit. That result belongs at the top of this page, not buried under decades of encouraging cell-culture data, because a negative trial is the strongest piece of evidence this entire four-part series has found for any claim about this herb.

Table of Contents

  1. The Claim
  2. The 2017 Lupus Trial: Negative, and Worth Reading in Full
  3. The Anti-Inflammatory Mechanism in Cell Culture
  4. The Anticancer Cell-Line Survey
  5. Xanthorrhizol Combined With Curcumin: A Real Synergy Finding
  6. The One In-Vivo Anti-Metastatic Study
  7. Pharmacokinetics: What Changed Since the EU Review, and What Has Not
  8. Drug Metabolism and Chemotherapy Interactions
  9. A Finding Worth a Caution: Estrogenic Activity
  10. Verdict and Evidence Tier
  11. What Is Not Known
  12. Practical Cautions
  13. Key Research Papers
  14. Connections

The Claim

Xanthorrhizol is a bisabolane sesquiterpenoid, found in meaningful quantity in essentially no plant besides Curcuma xanthorrhiza, and it is the focus of roughly two decades of steady laboratory work, much of it from a single research group at Yonsei University in Korea. The claims built on that work are broad: anti-inflammatory, anticancer, antioxidant, and (covered on a separate page) antimicrobial. This page covers the first two, which share overlapping cell-signalling mechanisms and are usually discussed together in the primary literature itself.

The 2017 Lupus Trial: Negative, and Worth Reading in Full

Wahono and colleagues, working at Brawijaya University and Saiful Anwar General Hospital in Malang, Indonesia, published a double-blind randomised controlled trial in the International Journal of Rheumatology in 2017, registered as NCT03155477. The design: patients with active systemic lupus erythematosus (SLEDAI score >3) and low vitamin D (25(OH)D3 ≤30 ng/mL) were split into two groups, both receiving cholecalciferol (vitamin D3) 3×400 IU daily for three months. Group I additionally received placebo; Group II additionally received Curcuma xanthorrhiza 3×20 mg daily (60 mg/day total) — the rhizome extract itself, not isolated curcumin or xanthorrhizol. The rationale, stated in the paper: curcumin is an immunomodulator with a biological effect the authors describe as similar to vitamin D, so the combination was hypothesised to work synergistically.

The outcome measures were SLEDAI (a validated lupus disease-activity score), serum interleukin-6 (IL-6, a pro-inflammatory cytokine), and serum TGF-β1 (a regulatory cytokine), all measured before and after treatment. The result, stated by the authors without hedging: “Curcuma xanthorrhiza supplementation on vitamin D3 had no effects on SLEDAI and serum levels of IL-6 and TGF-β1” — no significant difference between the group that received it and the group that received vitamin D3 alone.

This deserves to be named plainly as a negative result in the strongest sense used on this site: a real disease population, a validated clinical outcome measure (not a surrogate), an active pro-inflammatory biomarker panel, a registered protocol, and a double-blind, placebo-controlled design — and no signal on any of the three endpoints. It is a small trial (typical for a single-centre Indonesian rheumatology unit) and it tested one disease, one dose, and one combination (with vitamin D3, not alone), so it cannot be generalised to every inflammatory condition xanthorrhizol’s cell-culture data might suggest. But within its own scope, this is a properly designed test of an anti-inflammatory claim for the whole herb, and it failed. Every cell-culture and rodent finding below should be read with this result in mind, not the reverse.

Back to Table of Contents

The Anti-Inflammatory Mechanism in Cell Culture

The mechanistic literature is genuinely rich, and largely consistent across independent papers. In cultured macrophages and other cell models, xanthorrhizol suppresses production of nitric oxide (NO) and prostaglandin E2 (PGE2), and reduces expression of the enzymes that generate them — inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). A 2005 paper found antioxidant and anti-inflammatory activity in hippocampal neurons and primary glial cultures at 10 µM concentrations. A 2007 Carcinogenesis paper found that topical xanthorrhizol inhibited acute inflammation and blocked a two-stage skin tumour-promotion protocol in mice — connecting the inflammation and cancer mechanisms directly in a single in-vivo model. A more recent (2022) paper extended the anti-inflammatory finding to a rat model of Freund’s complete adjuvant-induced arthritis, reporting reduced oxidative stress and inflammatory markers.

This is a coherent, multiply-replicated mechanism — suppression of the NF-κB-linked inflammatory cascade — demonstrated in neurons, macrophages, skin and joint tissue, across cell culture and rodent models, by more than one independent research group. It is also, without the 2017 trial above, exactly the kind of preclinical picture that looks compelling until it meets a real disease population.

The Anticancer Cell-Line Survey

The cancer literature is the largest single body of xanthorrhizol research, spanning cell lines from at least six different tumour types:

A dedicated 2022 review in Phytomedicine, titled simply “Xanthorrhizol, a potential anticancer agent, from Curcuma xanthorrhiza Roxb.,” consolidates this literature and is a reasonable single starting point for a reader who wants the full picture. The consistent thread across every one of these studies, without exception: cell culture or rodent xenograft, never a human cancer patient. No trial has tested xanthorrhizol, in any form, as a cancer treatment or adjunct in a person.

Back to Table of Contents

Xanthorrhizol Combined With Curcumin: A Real Synergy Finding

One paper deserves individual attention for its precision. Cheah and colleagues (2009, Cancer Cell International) tested xanthorrhizol and curcumin, alone and combined, against human breast cancer cells. Xanthorrhizol alone: GI50 (the concentration producing 50% growth inhibition) of 15 µM. Combined with curcumin at a 3:7 to 1:9 xanthorrhizol-to-curcumin ratio: GI50 dropped to 5 µM — a genuine synergistic effect, not merely additive, and one that specifically requires curcumin’s presence to appear. This matters for how the whole-rhizome extract should be understood: Curcuma xanthorrhiza naturally contains both xanthorrhizol and curcuminoids (at lower concentration than C. longa, as the main page establishes), so this in-vitro synergy is at least a plausible reason the whole extract might outperform either purified compound alone — a hypothesis, not yet tested against a cancer outcome in any living organism.

The One In-Vivo Anti-Metastatic Study

Choi and colleagues (2005, Biochemical and Biophysical Research Communications) injected xanthorrhizol (0.2–1.0 mg/kg body weight) into mice with an induced lung metastasis model and found a genuine anti-metastatic effect — fewer metastatic lung nodules in treated animals. This is the one finding in the whole-body/whole-animal category that moves beyond a cell dish, and it is worth noting precisely what it does and does not show: it tested an already-established metastasis model, injected (not oral) xanthorrhizol, and a single tumour type. It is a genuine positive signal, not a demonstrated cancer treatment, and the dose (up to 1 mg/kg, injected) bears no straightforward relationship to any oral human intake.

Back to Table of Contents

Pharmacokinetics: What Changed Since the EU Review, and What Has Not

The European Medicines Agency’s 2012 literature review, discussed in full on the digestion and regulatory deep-dive, stated flatly: “There are no pharmacokinetic data for xanthorrhizol.” That gap has been partly filled since: a 2022 study in Food Science and Biotechnology measured xanthorrhizol pharmacokinetics directly in mice and rats, finding a terminal half-life of roughly 8 hours in mice and absolute oral bioavailability of only 10.2% in mice and 12.9–13.4% in rats — meaning roughly seven-eighths to nine-tenths of an oral dose never reaches systemic circulation at all, consistent with the poor-bioavailability pattern already documented for curcumin itself.

This is genuinely new information the EU assessors did not have, and it cuts against the optimistic reading of the cell-culture data above: the effective concentrations used in vitro (typically low micromolar) are achieved directly in a dish, with no absorption barrier to cross, while an oral dose in a living animal loses roughly seven-eighths to nine-tenths of its content before reaching the bloodstream. No human pharmacokinetic study of xanthorrhizol exists — this 2022 finding is rodent-only, and remains the newest and only PK data of any kind for this specific compound.

Drug Metabolism and Chemotherapy Interactions

Curcumin — the shared constituent, not xanthorrhizol specifically — is a potent inhibitor of cytochrome P450 enzymes CYP2C9 and CYP3A4, and a moderate inhibitor of CYP2B6, CYP1A2 and CYP2D6, per the EU assessment report’s pharmacokinetic review. CYP3A4 alone metabolises roughly 80% of drugs on the market. One human randomised, placebo-controlled crossover trial (Volak et al., 2013) directly tested this at high dose — 4 g curcuminoids plus 24 mg piperine, taken by healthy volunteers — against three probe drugs (midazolam, flurbiprofen, paracetamol) and found no significant effect on any of their metabolism, suggesting the strong in-vitro CYP-inhibition signal does not translate into a clinically detectable interaction at that human-tested dose. This is a genuine reassurance for that specific high-dose combination, though it does not rule out an effect at other doses, with other substrates, or from xanthorrhizol specifically, which has not been tested this way at all.

The practical relevance is sharpest for chemotherapy: cisplatin protection data are discussed on the liver deep-dive, and any patient on a chemotherapeutic agent metabolised by CYP3A4 (a very large share of them) should not assume the Volak reassurance automatically extends to their specific drug and dose without discussing it with their oncology team first.

Back to Table of Contents

A Finding Worth a Caution: Estrogenic Activity

A 2009 paper (Anggakusuma et al., Biological & Pharmaceutical Bulletin) found that xanthorrhizol, at 0.5–5 µM in vitro, induces estrogen-dependent gene expression — a signal of estrogenic activity. This is a single in-vitro finding, not confirmed in an animal or human study, and it should not be overstated. It is, however, directly relevant to the MCF-7 (hormone-receptor-positive breast cancer) work discussed above, where the same compound was tested against a hormone-driven cancer cell line in combination with tamoxifen, a drug that works by blocking estrogen signalling. A compound with its own estrogenic activity being combined with an anti-estrogen drug is a mechanistic tension worth naming rather than glossing over — the net effect of that specific combination in the 2014 in-vivo tamoxifen study was reported as beneficial, but the estrogenic-activity finding is a real reason for anyone with a hormone-sensitive cancer history to discuss concentrated xanthorrhizol extracts with an oncologist rather than assume “anticancer” automatically means safe in that context.

Verdict and Evidence Tier

Back to Table of Contents

What Is Not Known

  1. No human trial has tested xanthorrhizol, isolated or as part of a standardised extract, for any cancer, inflammatory condition besides the one negative lupus trial, or any other clinical indication.
  2. No human pharmacokinetic data exist for xanthorrhizol at all — only the 2022 rodent bioavailability study.
  3. No dose-finding study connects the in-vitro effective concentrations (typically low single-digit to tens of micromolar) to any achievable human oral dose, especially given the low (10–13%) rodent oral bioavailability.
  4. No study has replicated the 2017 negative SLE trial, tested a higher dose, tested xanthorrhizol specifically rather than the whole extract, or tested any other autoimmune or inflammatory disease.
  5. No genotoxicity, carcinogenicity or reproductive toxicity testing has been performed on xanthorrhizol itself, as distinct from the whole herbal substance (also untested on these endpoints, per the EU assessment report).

Practical Cautions

Nobody with cancer or an inflammatory autoimmune condition should read the cell-culture and rodent literature above as evidence that xanthorrhizol or temulawak extract will help — the one disease population actually tested (systemic lupus erythematosus) showed no benefit in a properly controlled trial. Anyone on chemotherapy, an immunosuppressant, or any drug with a narrow therapeutic index should discuss concentrated xanthorrhizol or Curcuma xanthorrhiza extracts with their prescribing physician first, given the CYP3A4/CYP2C9 interaction potential discussed above. Anyone with a hormone-receptor-positive cancer history should apply the same caution given the estrogenic-activity finding, pending better data.

Back to Table of Contents

Key Research Papers

  1. Wahono CS, Diah Setyorini C, Kalim H, Nurdiana N, Handono K. Effect of Curcuma xanthorrhiza supplementation on systemic lupus erythematosus patients with hypovitamin D. International Journal of Rheumatology. 2017;2017:7687053. The negative double-blind RCT discussed in full above.
  2. Ismail A. Xanthorrhizol induces apoptosis via the up-regulation of bax and p53 in HeLa cells. Anticancer Research. 2005;25(3B).
  3. Kang YJ, et al. Xanthorrhizol, a natural sesquiterpenoid, induces apoptosis and growth arrest in HCT116 human colon cancer cells. Journal of Pharmacological Sciences. 2009;111(3).
  4. (R)-(–)-Xanthorrhizol inhibits the migration and invasion of triple-negative breast cancer cells. Planta Medica. 2024.
  5. Cheah YH, Nordin FJ, Sarip R, et al. Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells. Cancer Cell International. 2009;9. The quantified synergy finding.
  6. Choi MA, et al. Xanthorrhizol, a natural sesquiterpenoid from Curcuma xanthorrhiza, has an anti-metastatic potential in experimental mouse lung metastasis model. Biochemical and Biophysical Research Communications. 2005;326(1).
  7. Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage skin carcinogenesis. Carcinogenesis. 2007;28(6).
  8. Kang J, Won J, Hwang JK, Kang W. Bioavailability of xanthorrhizol following oral administration of a supercritical extract of Java turmeric. Food Science and Biotechnology. 2022;31(10). The rodent pharmacokinetic finding.
  9. Volak LP, Ghirmai S, Cashman JR, Court MH. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology. 2013;75(2). The human CYP-interaction trial.
  10. Anggakusuma, Yanti, Hwang JK. Estrogenic activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. Biological & Pharmaceutical Bulletin. 2009;32(9).
  11. Xanthorrhizol, a potential anticancer agent, from Curcuma xanthorrhiza Roxb. Phytomedicine. 2022;104. The consolidated review.
  12. Xanthorrhizol and apoptosis/cancer — live search.

Connections

Back to Table of Contents